Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Advanced Micro Devices - Moderated (AMD) -- Ignore unavailable to you. Want to Upgrade?

To: Dan3 who wrote (85471)	7/22/2002 10:09:37 AM
From: Joe NYC	Respond to of 275872

Dan, Chips like Alpha, Power4, Itanium, and PA-Risc are dropping one by one. You can add Sparc to the list endagered species, and PowerPC as well, even though it is not a server chip, generally, it is a non-x86 CPU struggling to compete. Joe

To: Dan3 who wrote (85471)	7/22/2002 3:36:23 PM
From: Monica Detwiler	Respond to of 275872

This is precisely the kind of application that would do a lot better on systems that had more registers and a flat, 64-bit address space. So is this one: Monday July 22, 12:01 pm Eastern Time Press Release SOURCE: ViaLogy Corp. ViaLogy, Intel Collaborate on High-Throughput Integrated Multi-Vendor Microarray Analysis Based on Intel Itanium 2 Platforms Technology Platform Has Potential for Groundbreaking Detection, Validation and Quantization of Biological Samples for the Drug Discovery and Development Industry PASADENA, Calif.--(BUSINESS WIRE)--July 22, 2002-- ViaLogy Corp., in close collaboration with Intel Corporation, has developed a breakthrough computational technology that substantially increases the performance of critical DNA microarray devices and is based on the Intel® Itanium® 2 processor. The patented technology is an advanced bio-signal processing technology that enhances the utility and performance of drug discovery and development instruments and platforms by enabling current instruments to detect biological and chemical events (signals) up to 10,000 times lower than background noise. This innovation is a paradigm shift in the life sciences field where all signal processing relies on, and is restricted by, conventional passive analysis where a signal must be some measurable parameter greater than background to be discriminated from it. This breakthrough will increase the rate of adoption of arrayed bioinstrumentation, yielding time and cost savings for drug discovery and development, and could result in new scientific and medical discoveries. ViaLogy has worked with Intel as an early Itanium Processor family developer collaborator. Along with other companies in the U.S., including Hewlett-Packard and Oracle, ViaLogy received early Itanium 2 production systems from Intel for its internal development programs. ViaLogy is expanding its product offering and technology applications by developing an enterprise version of its Quantum Resonance Interferometry technology for drug discovery and development companies based on the Itanium 2 processor. The computational challenges facing ViaLogy in this project are daunting, and stress existing computing systems in maximizing speed and effective execution in a heavily cost-conscious environment. ViaLogy is focused on developing an integrated enterprise-class software solution to simultaneous automated analysis of large-scale microarray, protein array and cellular imaging assays comprising 100s to 1,000s of images with datasets ranging from 10s of MB to 100s of gigabytes. "In our differential expression and protein-protein interaction studies using high-density platforms, we found that very rapidly we run against the inherent limitations of a 32-bit platform in addressing large datasets. The Itanium processor provides an excellent scale-up alternative for our customers who have a significant bioinformatics production software investment on the Windows and Linux Intel-based servers and clusters," said Dr. Sandeep Gulati, Chief Scientific Officer of ViaLogy. "As we progress to computational solutions optimized for deployment on fine-grained grid clusters and utility computing paradigm, the price-performance payoff from the Intel Itanium® 2 processors investment is enormous." "We are very flattered to be included among global IT leaders in the Itanium 2 development effort," said Douglas C. Lane, President and CEO of ViaLogy. "With the Intel® Itanium® 2 processor now in the hands of our world-class scientists and development team, we are no longer constrained from pushing the limits of our technology and tackling some of the most challenging drug discovery problems facing the industry today. Two of the greatest strengths of the Intel® Itanium® 2 processor are its performance capabilities in extreme technical applications and its simultaneous capability to deliver powerful performance in a demanding enterprise environment. "Intel® Itanium® 2-based systems can not only advance the capabilities of our growing company, but also potentially contribute to advancing medical research through our technology applications, now enabled as an enterprise solution." "ViaLogy's innovative technology and the terrific results they are seeing is a great reflection of the performance that Itanium 2-based systems offer and the benefit this performance can provide to those in the life sciences field," said Lisa Hambrick, director, enterprise processor marketing for Intel's Enterprise Platform Group. "We are proud to see Intel technology powering these types of workloads, and hope that the cost savings and research can quicken life science discoveries and development." About ViaLogy Corp. ViaLogy is a technology development company that discovered and developed a revolutionary active signal processing technology. Using its patented Quantum Resonance Interferometry, the company enables dramatic increases in detection sensitivity of DNA microarrays and other biochip platforms. ViaLogy is a portfolio company of ViaSpace Technologies (www.viaspace.com), formed to commercialize world-class technologies originating from Caltech/NASA Jet Propulsion Laboratory and other government and university entities. For more information, please visit www.vialogy.com. Note: Itanium is a trademark or registered trademark of Intel Corporation or its subsidiaries in the United States and other countries. -------------------------------------------------------------------------------- Contact: ViaLogy Corp., Pasadena A.J. Abdallat, 626/296-6315 abdallat@vialogy.com vialogy.com